AgeX Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of therapeutics for age-related degenerative diseases in the United Stated. The company is developing AGEX-BAT1 and AGEX-VASC1, which are cell-based approaches in the preclinical stage of development to correct metabolic imbalances in aging; and to restore vascular support in ischemic tissues. It is also involved in the development of AGEX-iTR1547, a drug-based formulation in preclinical development for restoring regenerative potential in various aged tissues afflicted with degenerative diseases. In addition, the company develops Renelon, a first-generation tissue regeneration product designed to promote scarless tissue repair. Further, it markets genomic interpretation algorithms; and Cytiva, including pluripotent stem cell derived heart muscle cells used in screening drugs for efficacy and safety. The company was founded in 2017 and is based in Alameda, California. AgeX Therapeutics, Inc.(AMEX:AGE) operates independently of BioTime, Inc. as of November 28, 2018.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone510-871-4190
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$1.40 million
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date11/13/2019 (Estimated)
OptionableNot Optionable
AgeX Therapeutics (NYSE:AGE) Frequently Asked Questions
What is AgeX Therapeutics' stock symbol?
AgeX Therapeutics trades on the New York Stock Exchange (NYSE) under the ticker symbol "AGE."
How were AgeX Therapeutics' earnings last quarter?
AgeX Therapeutics (NYSE:AGE) posted its earnings results on Wednesday, August, 14th. The company reported ($0.08) earnings per share (EPS) for the quarter. The company earned $0.38 million during the quarter. View AgeX Therapeutics' Earnings History.
When is AgeX Therapeutics' next earnings date?
Has AgeX Therapeutics been receiving favorable news coverage?
News coverage about AGE stock has been trending somewhat negative this week, according to InfoTrie Sentiment Analysis. The research firm identifies negative and positive media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. AgeX Therapeutics earned a coverage optimism score of -1.2 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View News Stories for AgeX Therapeutics.
Who are some of AgeX Therapeutics' key competitors?
Some companies that are related to AgeX Therapeutics include resTORbio (TORC), ProQR Therapeutics (PRQR), Seres Therapeutics (MCRB), MannKind (MNKD), Provention Bio (PRVB), Xeris Pharmaceuticals (XERS), Evofem Biosciences (EVFM), Osmotica Pharmaceuticals (OSMT), Applied Therapeutics (APLT), Xenon Pharmaceuticals (XENE), Albireo Pharma (ALBO), Galectin Therapeutics (GALT), Stealth BioTherapeutics (MITO), Mallinckrodt (MNK) and Aeglea Bio Therapeutics (AGLE).
What other stocks do shareholders of AgeX Therapeutics own?
Who are AgeX Therapeutics' key executives?
AgeX Therapeutics' management team includes the folowing people:
- Mr. Alfred D. Kingsley, Exec. Chairman (Age 75)
- Dr. Michael D. West, Pres, CEO & Director (Age 65)
- Mr. Russell L. Skibsted, Chief Financial Officer (Age 59)
- Mr. Nafees Naseer Malik, Chief Operating Officer
- Dr. Aubrey D. N. J. de Grey BA, MA,Ph.D., Vice-Pres of New Technology Discovery
Who are AgeX Therapeutics' major shareholders?
Which major investors are selling AgeX Therapeutics stock?
How do I buy shares of AgeX Therapeutics?
Shares of AGE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is AgeX Therapeutics' stock price today?
One share of AGE stock can currently be purchased for approximately $1.70.
How big of a company is AgeX Therapeutics?
What is AgeX Therapeutics' official website?
How can I contact AgeX Therapeutics?
AgeX Therapeutics' mailing address is 1010 ATLANTIC AVENUE SUITE 102, ALAMEDA CA, 94501. The company can be reached via phone at 510-871-4190.
MarketBeat Community Rating for AgeX Therapeutics (NYSE AGE)
MarketBeat's community ratings are surveys of what our community members think about AgeX Therapeutics and other stocks. Vote "Outperform" if you believe AGE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AGE will underperform the S&P 500 over the long term. You may vote once every thirty days.
